608 related articles for article (PubMed ID: 11406724)
1. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Proimos G
J Thromb Thrombolysis; 2001 Apr; 11(2):99-110. PubMed ID: 11406724
[TBL] [Abstract][Full Text] [Related]
2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
Hobbach HP; Schuster P
Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
[TBL] [Abstract][Full Text] [Related]
4. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
Kereiakes DJ; Lorenz T; Young JJ; Kukielka G; Mueller MN; Nanniazzi-Alaimo L; Phillips DR
J Thromb Thrombolysis; 2001 Oct; 12(2):123-7. PubMed ID: 11729363
[TBL] [Abstract][Full Text] [Related]
6. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
7. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
[TBL] [Abstract][Full Text] [Related]
8. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
Marciniak SJ; Jordan RE; Mascelli MA
Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
[TBL] [Abstract][Full Text] [Related]
9. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Li Y; Spencer FA; Ball S; Becker RC
J Thromb Thrombolysis; 2000 Aug; 10(1):69-76. PubMed ID: 10947916
[TBL] [Abstract][Full Text] [Related]
11. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial.
PRICE Investigators
Am Heart J; 2001 Mar; 141(3):402-9. PubMed ID: 11231437
[TBL] [Abstract][Full Text] [Related]
12. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Leclerc JR
Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
[TBL] [Abstract][Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
Young JJ; Kereiakes DJ
J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194
[TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Lincoff AM; Califf RM; Topol EJ
J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
[TBL] [Abstract][Full Text] [Related]
15. Current issues with glycoprotein IIb-IIIa antagonists.
Schneider DJ
Curr Drug Targets; 2011 Nov; 12(12):1813-20. PubMed ID: 21718238
[TBL] [Abstract][Full Text] [Related]
16. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
17. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
Tcheng JE
Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
[No Abstract] [Full Text] [Related]
18. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
[TBL] [Abstract][Full Text] [Related]
19. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates.
Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ
J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
King S; Short M; Harmon C
Vascul Pharmacol; 2016 Mar; 78():10-6. PubMed ID: 26187354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]